Affiliation:
1. Laboratory of Metabolism (Y.Z., K.W.K., C.C., F.J.G.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892;
2. Institute of Pharmacology (J.R.I.), First Faculty of Medicine, Charles University, 128 00 Praha 2, Czech Republic
Abstract
AbstractPeroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor with manifold effects on intermediary metabolism. To define a set of urinary biomarkers that could be used to determine the efficacy of PPARα agonists, a metabolomic investigation was undertaken in wild-type and Pparα-null mice fed for 2 wk either a regular diet or a diet containing the PPARα ligand Wy-14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid), and their urine was analyzed by ultra-performance liquid chromatography coupled with time-of-flight mass spectrometry. Principal components analysis of 6393 accurate mass positive ions revealed clustering as a single phenotype of the treated and untreated Pparα (−/−) mice plus two additional discrete phenotypes for the treated and untreated Pparα (+/+) mice. Biomarkers of PPARα activation were identified from their accurate masses and confirmed by tandem mass spectrometry of authentic compounds. Biomarkers were quantitated from raw chromatographic data using appropriate calibration curves. PPARα urinary biomarkers highly statistically significantly elevated by Wy-14,643 treatment included 11β-hydroxy-3,20-dioxopregn-4-en-21-oic acid (>3700-fold), 11β,20-dihydroxy-3-oxopregn-4-en-21-oic acid (50-fold), nicotinamide (>2-fold), nicotinamide 1-oxide (5-fold), 1-methylnicotinamide (1.5-fold), hippuric acid (2-fold), and 2,8-dihydroxyquinoline-β-d-glucuronide (3-fold). PPARα urinary biomarkers highly statistically significantly attenuated by Wy-14,643 treatment included xanthurenic acid (1.3-fold), hexanoylglycine (20-fold), phenylpropionylglycine (4-fold), and cinnamoylglycine (9-fold). These biomarkers arise from PPARα effects on tryptophan, corticosterone, and fatty acid metabolism and on glucuronidation. This study underscores the power of mass spectrometry-based metabolomics combined with genetically modified mice in the definition of monogenic metabolic phenotypes.
Subject
Endocrinology,Molecular Biology,General Medicine
Reference33 articles.
1. An overview on biological mechanisms of PPARs.;Kota;Pharmacol Res,2005
2. Peroxisome proliferator-activated receptor-α and liver cancer: where do we stand?;Peters;J Mol Med,2005
3. Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse.;Reddy;Arch Int Pharmacodyn Ther,1977
4. Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver.;Reddy;Cancer Res,1979
5. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators.;Lee;Mol Cell Biol,1995
Cited by
67 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献